LDS/Medical Tests/Apolipoprotein A-I (APOA1) Gene Analysis

Apolipoprotein A-I (APOA1) Gene Analysis

Apolipoprotein A-I (APOA1) gene encodes apolipoprotein A-1 (apoA1) protein, an important component of high density lipoproteins (HDL). apoA-1 protein attaches to cell membrane and facilitates the efflux of cholesterol and phospholipids out of the cell. It is also a cofactor of lecithin–cholesterol acyltransferase, promoting the esterification of cholesterol. Both functions facilitate the removal of excess cholesterol and phospholipids by HDL for redistribution and excretion through liver. Mutations in APOA1 gene can lead to HDL deficiency, increasing the risk of early onset cardiovascular diseases. Alteration of APOA1 gene may also lead to familial APOA1-associated amyloidosis. The variant protein product deposits more systemically than nonhereditary amyloidosis and mainly affects skins, eye, liver, heart, kidney and larynx. More than 50 APOA1 mutations have been described, among which at least 16 have been shown to be associated with familial amyloidosis. Two hot spots of mutations are regions spanning residues 50 to 93 and 170 to 178. Mutations in residues from 1 to 75 usually result in renal and hepatic amyloidosis; and mutations in residue from 170 to 178 are often associated with cutaneous, cardiac and laryngeal amyloidosis. The majority of the mutations are nucleotide substitutions with several exceptions of deletion and deletion/insertion.

Accurate diagnosis of APOA1-associated familial HDL deficiency and APOA1-associated familiar amyloidosis may also require ruling out the effect of mutations in other genes, such as adenosine triphosphate binding cassette transporter A1 (ABCA1) or lecithin-cholesterol acyltransferase (LCAT) in HDL deficiency patients, and transthyretin, APOA2, lysozyme, gelsolin, cystatin C, and fibrinogen alpha chain genes of familial amyloidosis.

  • Assist in the diagnosis and confirmation of familial HDL deficiency and familial APOA1-associated amyloidosis
  • Assist in the risk prediction of familial HDL deficiency and familial APOA1-associated amyloidosis
  • No reportable variation identified means a mutation was not detected. However, a negative result does not rule out the possibility that a genetic alteration is not identifiable by the methodology used or the possibility that rare polymorphisms leads to false-negative results
  • Detected variations are evaluated according to American College of Medical Genetics and Genomics (ACMG) recommendations, based on their known, predicted, or possible pathogenicity. In some cases, detected mutation could have undetermined significance or could be false-positive due to rare polymorphism

No reportable variants are identified (Negative for mutations analyzed)

DNA sequencing (conventional or next generation sequencing).

Whole blood (lavender/EDTA tube).

Stability

  • Ambient: 3-5 days
  • Refregirated: 7-14 days
Analysis of other genes that may contribute to familial amyloidosis and HDL deficiency, including transthyretin, APOA2, lysozyme, gelsolin, cystatin C, and fibrinogen alpha chain, adenosine triphosphate binding cassette transporter A1 (ABCA1) and lecithin-cholesterol acyltransferase (LCAT).
5-10 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login